Yagi M J, Zanjani M, Holland J F, Bekesi J G
Cancer Chemother Pharmacol. 1984;12(2):77-82. doi: 10.1007/BF00254593.
The cancericidal efficacy of a new synthetic tripeptide was demonstrated using both in vitro cultures and in vivo tumorigenic assays. The antitumor agent PTT.119 (p-F-Phe-m-bis-(2-chloroethyl)amino-Phe-Met ethoxy HCl) was highly effective against three virulent murine tumor models: the L1210 leukemia, MJY-alpha mammary tumor and B16 melanoma. Treatment of tumor cells for periods as short as 15 min to 4 h with concentrations of 1-50 micrograms PTT.119/ml irreversibly reduced tumor cell viability, as evidenced by vital dye exclusion and abrogation of tumor formation and prolongation of host survival. Examination of the sensitivity of mice to PTT.119 revealed that the in vitro antitumor activity of the synthetic tripeptide was exerted at concentrations easily attainable and well tolerated in vivo.
通过体外培养和体内致瘤试验证明了一种新合成三肽的抗癌效力。抗肿瘤剂PTT.119(对氟苯丙氨酸-间双(2-氯乙基)氨基苯丙氨酸-甲硫氨酸乙酯盐酸盐)对三种恶性小鼠肿瘤模型具有高效:L1210白血病、MJY-α乳腺肿瘤和B16黑色素瘤。用1-50微克PTT.119/毫升的浓度处理肿瘤细胞15分钟至4小时,可不可逆地降低肿瘤细胞活力,这通过活体染料排斥、肿瘤形成的消除以及宿主存活期的延长得到证明。对小鼠对PTT.119敏感性的检测表明,该合成三肽的体外抗肿瘤活性在体内易于达到且耐受性良好的浓度下发挥作用。